Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
The first step is a consultation
Athena was professional, friendly, and made everything easy
These are not standardized across all patients or all formulations
It sustains us and is delivered by LCU in a safe, reliable way
The mechanisms of action include: Enhancement of glucose-dependent insulin secretion Suppression of glucagon secretion Delay in gastric emptying Increased satiety and appetite suppression These effects collectively lead to improved glycemic control and significant weight reduction
US$ 22.79
US$ 24.17
US$ 24.48
US$ 21.99
US$ 29.09
US$ 21.92
US$ 20.81
US$ 21.64
US$ 28.34
